Federal Indictment in Tampa Charges Two in Counterfeit Ozempic Scheme

Federal Indictment in Tampa Targets Counterfeit Ozempic Scheme

A federal grand jury in Tampa returned an indictment charging two foreign nationals with conspiracy in connection with an alleged scheme to import and sell counterfeit Ozempic sourced from China and to defraud the United States, alongside charges of smuggling and selling counterfeit drugs, Westlaw Today reported. The indictment, unsealed on September 29, identifies the defendants as Swapnadip “Eric” Roy and Vicky Ramancha, both Dubai-based Indian nationals charged in the Middle District of Florida under United States v. Roy.

From July 2023 through April 2024, the defendants allegedly acquired products labeled as Ozempic from unauthorized Chinese sources, utilizing counterfeit containers, fake labels, and duplicate needles designed to deceive downstream purchasers, according to Alston & Bird. Despite the US Food and Drug Administration issuing a public safety alert regarding a counterfeit lot in December 2023 and seizing products from domestic warehouses, the distribution scheme allegedly persisted.

Using the Drug Supply Chain Security Act as an Import Compliance Standard

Although the indictment does not bring a standalone charge under the Drug Supply Chain Security Act, prosecutors utilized the statute’s documentation and unique serial number mandates as the foundation for smuggling charges that carry up to 20 years per count. Court documents show that a co-conspirator flagged duplicate serial numbers to Ramancha, noting that all pharmaceutical drugs in the United States must carry unique serial numbers per the 2018 legislation, and that trading partners are required to quarantine suspect products and file Form FDA 3911.

In response to those warnings, Ramancha allegedly urged associates to maintain strict confidentiality and avoid drawing scrutiny from regulatory authorities. The US Department of Justice used circumvention of the Drug Supply Chain Security Act’s documentation and serial number requirements as the basis for smuggling charges.

Authorities Track International Supply Chain Vulnerabilities

Law enforcement actions span international borders, with Roy arrested in Italy on an INTERPOL Red Notice and subsequently extradited to Tampa, while Ramancha remains at large. Parallel investigations opened by Indian authorities are tied to approximately 125,000 counterfeit doses, highlighting the scale of the distribution network. The high patient demand and supply constraints surrounding GLP-1 medications create strong pricing arbitrage incentives that illicit actors exploit to penetrate legitimate distribution channels.

For pharmaceutical facilities, quality assurance directors, and supply chain leads, the case demonstrates that standard track-and-trace controls and authorized distributor verification protocols face severe tests when anomalous pricing patterns emerge. The ongoing enforcement priority by the FDA Office of Criminal Investigations indicates that tracing illicit distribution networks remains central to protecting the pharmaceutical supply chain.

Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.